CN113766929A - 癌症治疗 - Google Patents

癌症治疗 Download PDF

Info

Publication number
CN113766929A
CN113766929A CN202080032326.6A CN202080032326A CN113766929A CN 113766929 A CN113766929 A CN 113766929A CN 202080032326 A CN202080032326 A CN 202080032326A CN 113766929 A CN113766929 A CN 113766929A
Authority
CN
China
Prior art keywords
biomaterial
agonist
polymeric
tumor
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080032326.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·S·戈尔德伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surge Therapeutics Inc
Original Assignee
Stimit Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stimit Corp filed Critical Stimit Corp
Publication of CN113766929A publication Critical patent/CN113766929A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080032326.6A 2019-05-02 2020-05-01 癌症治疗 Pending CN113766929A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962842068P 2019-05-02 2019-05-02
US62/842,068 2019-05-02
PCT/US2020/031169 WO2020223698A1 (en) 2019-05-02 2020-05-01 Cancer treatment

Publications (1)

Publication Number Publication Date
CN113766929A true CN113766929A (zh) 2021-12-07

Family

ID=73029386

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080032326.6A Pending CN113766929A (zh) 2019-05-02 2020-05-01 癌症治疗

Country Status (10)

Country Link
US (1) US20220218822A1 (https=)
EP (1) EP3962524A4 (https=)
JP (2) JP2022531184A (https=)
KR (1) KR20220004077A (https=)
CN (1) CN113766929A (https=)
AU (1) AU2020266676A1 (https=)
BR (1) BR112021021699A8 (https=)
CA (1) CA3132653A1 (https=)
IL (1) IL287652A (https=)
WO (1) WO2020223698A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230041032A (ko) * 2020-07-17 2023-03-23 서지 테라퓨틱스, 인크. 중합체 복합 제제를 포함하는 제제 및 조성물
AU2021329884A1 (en) * 2020-08-17 2023-02-16 SURGE Therapeutics, Inc. Immune modulation of myeloid derived suppressive cell function for cancer treatment
AU2022212114A1 (en) * 2021-01-30 2023-06-22 SURGE Therapeutics, Inc. Cancer therapy
KR102906748B1 (ko) * 2023-05-09 2025-12-31 국립부경대학교 산학협력단 아임계 수 가수분해를 이용한 갑각류 유래 올리고키토산의 제조방법, 이를 이용하여 제조된 올리고키토산 및 올리고키토산을 포함하는 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102892777A (zh) * 2010-03-19 2013-01-23 伊玛提克斯生物技术有限公司 用于治疗胃癌和其他癌症的抗肿瘤相关肽及相关抗癌疫苗组合物
US20160008399A1 (en) * 2013-01-14 2016-01-14 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
WO2018045058A1 (en) * 2016-08-30 2018-03-08 Dana-Farber Cancer Institute, Inc. Drug delivery compositions and uses thereof
CN108350062A (zh) * 2015-08-06 2018-07-31 达纳-法伯癌症研究所股份有限公司 靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965379A (en) * 1991-07-19 1999-10-12 Cytimmune Sciences Inc. Method for measuring endogenous cytokines
EP0820305A2 (en) 1995-04-04 1998-01-28 Wound Healing of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
US6756363B1 (en) 2000-11-17 2004-06-29 Wound Healing Of Oklahoma, Inc. Solutions and films of glycated chitosan
AU2003243608A1 (en) * 2002-06-20 2004-01-06 Royer Biomedical, Inc. Resorbable delivery systems for the treatment of cancer
RU2288730C2 (ru) * 2005-02-22 2006-12-10 Научно-исследовательский институт Эпидемиологии и микробиологии Сибирского отделения Российской академии наук (НИИ ЭМ СО РАМН) Способ лечения онкогинекологических больных и гель для его осуществления
EP1942950A2 (en) * 2005-11-01 2008-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Biodegradable composite for internal local radiotherapy
EP3831393A1 (en) 2012-01-20 2021-06-09 Immunophotonics, Inc. Chitosan-derived compositions
US11111316B2 (en) 2012-01-20 2021-09-07 Immunophotonics, Inc. Chitosan-derived compositions
AU2017255833B2 (en) * 2016-04-25 2022-09-01 Mizhou Hui Application of small-molecule hyaluronic acid fragment
WO2018088933A1 (en) * 2016-11-14 2018-05-17 Limited Liability Company "Panacela Labs" Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102892777A (zh) * 2010-03-19 2013-01-23 伊玛提克斯生物技术有限公司 用于治疗胃癌和其他癌症的抗肿瘤相关肽及相关抗癌疫苗组合物
US20160008399A1 (en) * 2013-01-14 2016-01-14 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
CN108350062A (zh) * 2015-08-06 2018-07-31 达纳-法伯癌症研究所股份有限公司 靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应
WO2018045058A1 (en) * 2016-08-30 2018-03-08 Dana-Farber Cancer Institute, Inc. Drug delivery compositions and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
郑美玲: "羧甲基壳聚糖对肿瘤细胞及组织生长影响的研究", 《中国优秀硕士学位论文全文数据库-医药卫生科技辑》, no. 06 *
顾炎;曹雪涛;: "模式识别受体与肿瘤微环境研究进展", 中国肿瘤生物治疗杂志, no. 02, pages 143 - 150 *

Also Published As

Publication number Publication date
BR112021021699A2 (pt) 2022-03-22
WO2020223698A1 (en) 2020-11-05
EP3962524A1 (en) 2022-03-09
IL287652A (en) 2021-12-01
JP2022531184A (ja) 2022-07-06
US20220218822A1 (en) 2022-07-14
AU2020266676A1 (en) 2021-09-30
KR20220004077A (ko) 2022-01-11
EP3962524A4 (en) 2023-06-14
JP2024151337A (ja) 2024-10-24
CA3132653A1 (en) 2020-11-05
BR112021021699A8 (pt) 2023-04-25

Similar Documents

Publication Publication Date Title
JP2024151337A (ja) がんの処置
JP2020075940A (ja) 免疫療法のための調節粒子
US20230293427A1 (en) Preparations and compositions comprising polymer combination preparations
CA3193244A1 (en) Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
AU2017375793B2 (en) Microparticles and nanoparticles having negative surface charges
Wafa et al. Single dose of a polyanhydride particle-based vaccine generates potent antigen-specific antitumor immune responses
CN116322702A (zh) 用于癌症治疗的髓源性抑制性细胞功能的免疫调节
US20240082236A1 (en) Cancer therapy
KR20240107169A (ko) 핵산 조성물 및 이의 용도
US20250032478A1 (en) Solid forms of resiquimod and formulations thereof
CN116472040A (zh) 用于自身免疫性疾病和过敏治疗的方法、组合物和治疗性疫苗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Massachusetts

Applicant after: Sage therapy

Address before: Massachusetts

Applicant before: Stimit Co.

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20211207

RJ01 Rejection of invention patent application after publication